PDGF Results Timeline: What Studies Measured, and When

The short answer from the literature

There is no established week-by-week timeline for PDGF in humans. The published record is dominated by mechanistic and animal work, alongside reviews describing PDGF as one of several growth factors released by platelets during tissue repair, such as the 2022 review of the regenerative capacity of platelets in modern medicine (PMID 34924312). The clearest human datapoint is a prospective, randomized, controlled trial in which researchers reported improved aesthetic results and patient satisfaction with recombinant pure PDGF following radiofrequency microneedling (PMID 40937942). Beyond that, timing evidence is preclinical and is labeled as such throughout this page.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions. Nothing here describes a regimen, a schedule, or an expected personal outcome.

Why "how long does PDGF take to work" is hard to answer from the literature

Three structural problems make a clean timeline impossible to extract:

• Different PDGF entities. Studies examined PDGF-A, PDGF-B, PDGF-C, whole recombinant PDGF protein, and synthetic PDGF-mimetic peptides — not one interchangeable molecule. A supramolecular hydrogel microsphere carrying a PDGF mimetic peptide, for example, was tested for recovery after spinal cord injury (PMID 36787636), a very different construct from platelet-derived preparations reviewed in 2022 (PMID 34924312).
• Different directions of interest. Some work asked whether adding PDGF signalling helped; other work asked whether blocking it helped. An inhibitory aptamer against PDGF-C was studied for reducing choroidal neovascularization and fibrosis in the setting of anti-VEGF refractoriness (PMID 42138517).
• Different measurement windows. Endpoints ranged from acute blood–brain barrier integrity after thrombolysis (PMID 36587812) to chronic organ fibrosis in transgenic mice (PMID 27816607).

Human data: what was measured, and what the record does and does not specify

The randomized aesthetic trial

The most directly relevant human evidence is a 2025 prospective, randomized, controlled clinical trial published in the Journal of Cosmetic Dermatology, in which researchers evaluated recombinant pure PDGF applied in the context of radiofrequency microneedling and reported improved aesthetic results and greater patient satisfaction compared with the control condition (PMID 40937942). Because assessment intervals are not restated here beyond what the indexed record supports, readers looking for the exact follow-up schedule, scoring instruments, and participant numbers would need the full report (PMID 40937942). No second randomized human trial in the verified set replicates that finding, so the human timeline rests on a single study.

Biomarker measurement in human intervention studies

Growth-factor and inflammatory marker panels are sometimes tracked as secondary outcomes over an intervention period rather than as primary endpoints; a 2025 study in The Oncologist measured inflammatory markers alongside cancer progression during a whole food plant-based dietary intervention (PMID 40973844). That design illustrates how circulating signalling markers are sampled at scheduled visits, not how administered PDGF behaves in people.

Oncology timescales

In oncology, where receptor tyrosine kinase signalling is a therapeutic target rather than a supplement, outcomes are measured in treatment cycles and months. A 2017 report in Future Oncology described imatinib mesylate in desmoplastic small round cell tumors (PMID 28589771). That context is included only to show that PDGF-pathway research spans clinical timescales far longer than a cosmetic or wound endpoint.

Preclinical timelines (clearly labeled: animal and laboratory models)

The following findings come from animal or laboratory systems. Nothing in them translates to a human schedule, and none of them were performed to establish a consumer timeline.

Hours: acute vascular and barrier endpoints

In work published in Pharmacological Research in 2023, researchers reported that remote ischemic conditioning attenuated blood–brain barrier disruption after recombinant tissue plasminogen activator treatment, with reduction of PDGF-CC identified as part of the mechanism (PMID 36587812). Barrier-integrity endpoints of this kind are measured within the acute post-treatment window, not over weeks.

Days to weeks: repair and recovery models

A 2023 ACS Nano study reported that supramolecular hydrogel microspheres delivering a PDGF-mimetic peptide promoted recovery from spinal cord injury in a preclinical model (PMID 36787636). Functional recovery studies of this design typically follow animals through serial behavioural and histological assessments after a single implantation, and the relevant interval is set by the model, not by any human protocol.

Wound-healing reviews place PDGF among the growth factors and cytokines acting across the overlapping phases of repair — inflammation, proliferation, and remodelling — each of which occupies a different part of the healing course; the 2008 review in Wound Repair and Regeneration summarised those roles (PMID 19128254). The 2022 platelet review similarly framed platelet-released factors as contributors to regenerative processes rather than as agents with a fixed onset time (PMID 34924312).

Weeks to months: bone, heart, kidney and eye

Not every measured PDGF effect pointed in a favourable direction. A 2023 paper in npj Regenerative Medicine reported that PDGF inhibited BMP2-induced bone healing (PMID 36631491) — an outcome measured over a bone-repair window in which more signalling did not equal faster repair.

In transgenic mice, researchers reported that PDGF-A and PDGF-B induced cardiac fibrosis (PMID 27816607), an endpoint that accumulates over sustained exposure rather than appearing acutely. In the kidney, a 2026 Kidney International study reported that tubular cell-specific PDGF-B drove formation of fibrogenic niches in kidney fibrosis (PMID 41765181). In the eye, an inhibitory aptamer against PDGF-C was reported to overcome anti-VEGF refractoriness and reduce choroidal neovascularization and fibrosis (PMID 42138517). Ocular neovascularization models more generally use fixed post-induction assessment points, as in a 2023 International Ophthalmology study of adalimumab in an experimental corneal neovascularization model (PMID 37012439).

What was measured, where, and over what window

Adverse Events and Counter-Signals: What Studies Report

The verified literature contains more signals about unwanted PDGF activity than about adverse events from administered PDGF. Researchers reported PDGF-A and PDGF-B inducing cardiac fibrosis in transgenic mice (PMID 27816607), and tubular PDGF-B driving fibrogenic niches in kidney fibrosis (PMID 41765181). In the eye, PDGF-C inhibition was reported to reduce choroidal neovascularization and fibrosis (PMID 42138517), and in bone, PDGF was reported to inhibit BMP2-induced healing (PMID 36631491). The human randomized trial in the verified set was reported in the context of aesthetic outcomes and satisfaction following radiofrequency microneedling (PMID 40937942); its safety reporting is contained in the full publication rather than summarised here.

What the evidence does not establish

1. No validated week-by-week human schedule. Outside a single randomized aesthetic trial (PMID 40937942), the verified set contains no human trials reporting PDGF outcomes at defined 4-, 8- or 12-week checkpoints.
2. No cross-tissue generalisation. Findings in skin, bone, spinal cord, heart, kidney and eye moved in different directions, as the bone-healing and fibrosis reports illustrate (PMID 36631491, PMID 41765181).
3. No equivalence between platelet preparations and isolated PDGF. The 2022 review described platelet-derived regenerative applications as a broad category of mixed factors (PMID 34924312), which is not the same as a single recombinant protein.
4. No consumer-facing dosing literature. The verified papers describe experimental systems and clinical research settings; none provide a schedule intended for individual use.

How researchers frame repair timing generally

Reviews of wound repair describe growth factor activity as sequenced rather than instantaneous: signalling molecules including PDGF participate at different stages of healing, with early inflammatory signalling preceding proliferative and remodelling activity (PMID 19128254). That staged framing is the closest the literature comes to a general "timeline," and it describes biology in models and reviews — not a prediction for any individual. Readers new to the molecule can start with the background overview at PeptideU's PDGF learn page.

References

• Applications of the regenerative capacity of platelets in modern medicine (Cytokine & Growth Factor Reviews, 2022)
• Growth factors and cytokines in wound healing (Wound Repair and Regeneration, 2008)
• PDGF inhibits BMP2-induced bone healing (npj Regenerative Medicine, 2023)
• Recombinant Pure PDGF Improves Aesthetic Results and Patient Satisfaction Following RF Microneedling: A Prospective, Randomized, Controlled Clinical Trial (Journal of Cosmetic Dermatology, 2025)
• Tubular cell-specific platelet-derived growth factor-B drives formation of fibrogenic niches in kidney fibrosis (Kidney International, 2026)
• Supramolecular Hydrogel Microspheres of Platelet-Derived Growth Factor Mimetic Peptide Promote Recovery from Spinal Cord Injury (ACS Nano, 2023)
• Remote ischemic conditioning attenuates blood-brain barrier disruption after recombinant tissue plasminogen activator treatment via reducing PDGF-CC (Pharmacological Research, 2023)
• An Inhibitory Aptamer Against PDGF-C Overcomes Anti-VEGF Refractoriness and Reduces Choroidal Neovascularization and Fibrosis (Investigative Ophthalmology & Visual Science, 2026)
• Effect of a whole food plant-based dietary intervention on cancer progression and inflammatory markers (The Oncologist, 2025)
• PDGF-A and PDGF-B induces cardiac fibrosis in transgenic mice (Experimental Cell Research, 2016)
• Effect of adalimumab on experimental corneal neovascularization model (International Ophthalmology, 2023)
• Imatinib mesylate in desmoplastic small round cell tumors (Future Oncology, 2017)